Overview

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)

Status:
Completed
Trial end date:
2012-04-28
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID for 12 weeks will also be evaluated.
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Lifitegrast
Ophthalmic Solutions